ThromboGenics Appoints Emmanuèle Attout as Independent Non-Executive Director
(Thomson Reuters ONE) -
Leuven, Belgium - 22 January, 2015 - ThromboGenics NV (Euronext Brussels: THR),
an integrated biopharmaceutical company focused on developing and
commercializing innovative ophthalmic medicines, announces that its Board of
Directors has nominated Emmanuèle Attout to be its new Independent non-executive
director. Mrs. Attout will join the Audit Committee of the Company.
Mrs. Attout has been an audit partner at PricewaterhouseCoopers since 1994. She
has been in charge of audits of a range of clients including banks, insurance
companies, investment funds and assets managers. She has in recent years been
in charge of the audits of listed pharmaceuticals companies and life sciences
business out of which she brings substantial relevant experience to the Board
and to the Audit Committee.
Dr Staf Van Reet, Chairman of ThromboGenics' Board of Directors, said: "We are
delighted to welcome Emmanuèle to the ThromboGenics' board as a non-executive
director. Her broad business and financial experience, will be extremely
valuable to our Board and Audit Committee as we work to execute the standalone
strategy we announced in mid-2014."
Commenting on her appointment, Mrs. Attout said: "I am very pleased to be
joining the ThromboGenics Board. I have been impressed by the clear strategy
that the Company has outlined to build a profitable business focused on
providing innovative medicines for the treatment of a number of important
vitreo-retinal diseases and I am looking forward to contributing to its
successful execution."
END
For further information please contact:
+------------------------------------------+-----------------------------------+
| | |
|ThromboGenics |Citigate Dewe Rogerson |
| | |
|Wouter Piepers, |David Dible/Malcolm Robertson |
|Global Head of Corporate Communications &| |
|IR |Tel: +44 20 7282 2867 |
|+32 16 75 13 10 / +32 478 33 56 32 |Malcolm.robertson(at)citigatedr.co.uk |
|wouter.piepers(at)thrombogenics.com | |
| | |
+------------------------------------------+-----------------------------------+
About ThromboGenics
ThromboGenics is an integrated biopharmaceutical company focused on developing
and commercializing innovative ophthalmic and oncology medicines. The Company's
lead product, JETREA(® )(ocriplasmin), has been approved by the US FDA for the
treatment of symptomatic VMA and was launched in January 2013.
ThromboGenics signed a strategic partnership with Alcon, a division of Novartis,
for the commercialization of JETREA(®) outside the United States.
ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin, NJ
(US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels
exchange under the symbol THR. More information is available at
www.thrombogenics.com.
About JETREA(® )(ocriplasmin)
JETREA(® )(ocriplasmin) is a truncated form of human plasmin. In the US,
JETREA(®) is indicated for the treatment of symptomatic VMA. In Europe,
JETREA(®) is indicated for the treatment of vitreomacular traction (VMT),
including when associated with macular hole of diameter less than or equal to
400 microns. JETREA(®) is a selective proteolytic enzyme that cleaves
fibronectin, laminin and collagen, three major components of the vitreoretinal
interface that play an important role in vitreomacular adhesion.
JETREA(® )has been evaluated in two multi-center, randomized, double-masked
Phase III trials conducted in the U.S. and Europe involving 652 patients with
vitreomacular adhesion. Both studies met the primary endpoint of resolution of
VMA at day 28.
JETREA's Phase III program found that 26.5% of patients treated with ocriplasmin
saw resolution of VMA, compared with 10.1% of patients receiving placebo
(p<0.01). The Phase III program also showed that JETREA was generally well
tolerated with most adverse events being transient and mild in severity.
Important information about forward-looking statements
Certain statements in this press release may be considered "forward-looking".
Such forward-looking statements are based on current expectations, and,
accordingly, entail and are influenced by various risks and uncertainties. The
Company therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume an obligation to update or
revise any forward-looking statement, whether as a result of new information,
future events or any other reason. Additional information concerning risks and
uncertainties affecting the business and other factors that could cause actual
results to differ materially from any forward-looking statement is contained in
the Company's Annual Report.
This press release does not constitute an offer or invitation for the sale or
purchase of securities or assets of ThromboGenics in any jurisdiction. No
securities of ThromboGenics may be offered or sold within the United States
without registration under the U.S. Securities Act of 1933, as amended, or in
compliance with an exemption therefrom, and in accordance with any applicable
U.S. state securities laws.
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: ThromboGenics NV via GlobeNewswire
[HUG#1888777]
Unternehmensinformation / Kurzprofil:
Datum: 22.01.2015 - 10:00 Uhr
Sprache: Deutsch
News-ID 366174
Anzahl Zeichen: 6920
contact information:
Town:
Leuven
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 200 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ThromboGenics Appoints Emmanuèle Attout as Independent Non-Executive Director"
steht unter der journalistisch-redaktionellen Verantwortung von
ThromboGenics NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
